open access

Vol 47, No 2 (2009)
ORIGINAL PAPERS
Published online: 2009-12-10
Submitted: 2011-12-19
Get Citation

NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.

Marek Olakowski, Tomasz Tyszkiewicz, Michał Jarzab, Robert Król, Małgorzata Oczko-Wojciechowska, Małgorzata Kowalska, Monika Kowal, Grzegorz M Gala, Maciej Kajor, Dariusz Lange, Ewa Chmielik, Elzbieta Gubala, Paweł Lampe, Barbara Jarzab
DOI: 10.2478/v10042-009-0031-1
·
Folia Histochem Cytobiol 2009;47(2):249-255.

open access

Vol 47, No 2 (2009)
ORIGINAL PAPERS
Published online: 2009-12-10
Submitted: 2011-12-19

Abstract

The aim of the study was to analyze the gene expression profile of pancreatic cancer to derive novel molecular markers of this malignancy. The snap-frozen or RNA-later preserved samples of 18 pancreatic adenocarcinomas, 5 chronic pancreatitis cases and 6 specimens of grossly normal pancreas were used for microarray analysis by HG-U133 Plus 2.0 oligonucleotide Affymetrix arrays. Validation was carried out by real-time quantitative PCR (Q-PCR) in the set of 66 samples: 31 of pancreatic cancer, 14 of chronic pancreatitis and 21 of macroscopically unchanged pancreas. By Principal Component Analysis of the microarray data we found a very consistent expression pattern of normal samples and a less homogenous one in chronic pancreatitis. By supervised comparison (corrected p-value 0.001) we observed 11094 probesets differentiating between cancer and normal samples, while only seventy six probesets were significant for difference between cancer and chronic pancreatitis. The only gene occurring within the best 10 genes in both comparisons was S100 calcium binding protein P (S100P), already indicated for its utility as pancreatic cancer marker by earlier microarray-based studies. For validation we selected two genes which appeared as valuable candidates for molecular markers of pancreatic cancer: neuroblastoma, suppression of tumorigenicity 1 (NBL1) and anillin (ANLN). By Q-PCR, we confirmed statistically significant differences in these genes with a 9.5 fold-change difference between NBL1 expression in cancer/normal comparison and a relatively modest difference between cancer and pancreatitis. For ANLN even more distinct differences were observed (cancer/normal 19.8-fold, cancer/pancreatitis 4.0-fold). NBL1 and anillin are promising markers for pancreatic carcinoma molecular diagnostics.

Abstract

The aim of the study was to analyze the gene expression profile of pancreatic cancer to derive novel molecular markers of this malignancy. The snap-frozen or RNA-later preserved samples of 18 pancreatic adenocarcinomas, 5 chronic pancreatitis cases and 6 specimens of grossly normal pancreas were used for microarray analysis by HG-U133 Plus 2.0 oligonucleotide Affymetrix arrays. Validation was carried out by real-time quantitative PCR (Q-PCR) in the set of 66 samples: 31 of pancreatic cancer, 14 of chronic pancreatitis and 21 of macroscopically unchanged pancreas. By Principal Component Analysis of the microarray data we found a very consistent expression pattern of normal samples and a less homogenous one in chronic pancreatitis. By supervised comparison (corrected p-value 0.001) we observed 11094 probesets differentiating between cancer and normal samples, while only seventy six probesets were significant for difference between cancer and chronic pancreatitis. The only gene occurring within the best 10 genes in both comparisons was S100 calcium binding protein P (S100P), already indicated for its utility as pancreatic cancer marker by earlier microarray-based studies. For validation we selected two genes which appeared as valuable candidates for molecular markers of pancreatic cancer: neuroblastoma, suppression of tumorigenicity 1 (NBL1) and anillin (ANLN). By Q-PCR, we confirmed statistically significant differences in these genes with a 9.5 fold-change difference between NBL1 expression in cancer/normal comparison and a relatively modest difference between cancer and pancreatitis. For ANLN even more distinct differences were observed (cancer/normal 19.8-fold, cancer/pancreatitis 4.0-fold). NBL1 and anillin are promising markers for pancreatic carcinoma molecular diagnostics.
Get Citation
About this article
Title

NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 47, No 2 (2009)

Pages

249-255

Published online

2009-12-10

DOI

10.2478/v10042-009-0031-1

Bibliographic record

Folia Histochem Cytobiol 2009;47(2):249-255.

Authors

Marek Olakowski
Tomasz Tyszkiewicz
Michał Jarzab
Robert Król
Małgorzata Oczko-Wojciechowska
Małgorzata Kowalska
Monika Kowal
Grzegorz M Gala
Maciej Kajor
Dariusz Lange
Ewa Chmielik
Elzbieta Gubala
Paweł Lampe
Barbara Jarzab

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl